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Objectives: To assess the predictive value of neuropsychologic
profiles, at diagnosis, for mortality in incident Alzheimer disease
(AD).
Background: Rate of AD progression varies significantly across
individuals for reasons that are not well understood. Several
studies have linked rapid decline with disproportionately
impaired executive functioning, presumably reflecting greater
impairment of frontal networks. To the extent that differential
neuropsychologic profiles reflect various neuropathologic pre-
sentations of AD, such profiles may inform survival estimates
early in the disease.
Methods: Five neuropsychologic indices were used to character-
ize performance in 161 individuals at diagnosis of AD during a
15-year, longitudinal, primarily community-based study.
Results: Fifty-two percent of participants reached the mortality
end point with a median survival of 5.52 years (95% confidence
interval, 4.41-6.63). Cox proportional hazards analyses indi-
cated that older age at diagnosis was associated with higher
risk of mortality (risk ratios, 1.08; 95% confidence interval,
1.04-1.12) whereas Hispanic ethnicity predicted lower mortality
[0.22 (0.09-0.55)]. Controlling for these 2 demographic variables,
higher verbal fluency scores at diagnosis predicted lower
mortality [0.69 (0.49-0.96)].
Conclusions: Disproportionate impairment of both category and
letter fluency at the earliest stages of AD predicts mortality. The
prognostic value of these tests may derive from their general
psychometric properties, or may reflect the measures’ sensitivity
to an early or critical level of compromise to frontal networks.
Key Words: Alzheimer disease, mortality, verbal fluency,
prognosis, neuropsychology
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The median survival time after a diagnosis of Alzheimerdisease (AD) has been estimated at 7 to 10 years in
patients diagnosed in their 60s and 70s, and 3 years in
patients diagnosed in the eighth or ninth decade of life.1,2
However, rate of disease progression varies significantly
among individuals. Rapid decline has been linked to early
age of onset, male gender,3 concurrent physical illness,4
coexisting depression,5 extrapyramidal symptoms,6 gait
disturbance and vascular risk factors7; however, the
factors which determine individual rate of progression
are not well understood, particularly those identifiable
early in the course of AD. Marked global cognitive
impairment on the Mini-Mental State Examination8
seems to predict mortality most consistently4,9; however,
ceiling effects render this test less useful in early AD when
patients achieve relatively high scores.10 In contrast,
heterogeneous neuropsychologic profiles across indivi-
duals with early AD offer the opportunity to evaluate the
prognostic value of differential deficits in specific cogni-
tive domains for disease course, or mortality.11–13
Although patients with AD exhibit a core memory
deficit, there is considerable variability in performance on
measures of executive functioning, language, and visuos-
patial skills, so much so that various ‘‘subtypes’’ of AD
including frontal and posterior variants have been
described.12,14–17 Functional neuroimaging and neuro-
pathologic studies have suggested that distinct neuropsy-
chologic profiles map onto differential distributions of
neuropathology reflected through regional hypometabo-
lism11,18,19 and burden of amyloid plaques on autopsy.20
To the extent that various neuropathologic presentations
of AD may be related to differential survival rates,
analysis of neuropsychologic profiles at diagnosis has the
potential to inform prognosis early in the disease course.
Preliminary evidence from neuropsychologic19,21 and
neuroimaging19 investigations in patients with prevalent
AD has suggested that early and disproportionate
involvement of frontal networks may herald a more rapid
disease course. Overall, however, the relationship between
neuropsychologic profile and disease course has been
explored only minimally, and existing studies have not
followed patients from the earliest stages of AD until
mortality.
The current study evaluates the usefulness of 5
neuropsychologic indices measured at diagnosis, includ-
ing memory, abstract reasoning, language, visuospatial
functioning, and verbal fluency in predicting differential
mortality risk in patients with incident AD. Existing work
suggests that skills dependent on the integrity of frontalCopyright r 2006 by Lippincott Williams & Wilkins
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networks, such as abstract reasoning and verbal fluency,
may be particularly useful in predicting survival.41–43
MATERIALS AND METHODS
Participants
For the present analyses, AD patients were identi-
fied and followed through 2 cohorts described in more
detail in earlier work.22,23 Briefly, the first cohort
consisted of a community registry of subjects enrolled
between 1989 and 1992 from regional medical facilities
(inpatient and outpatient services and private practi-
tioners in the community), nursing homes serving local
residents, a state agency list of home care recipients,
senior centers and housing, volunteers or self-referred,
and some spouses of individuals identified as cases.
Because of the enrollment procedure of this cohort, it
may not be completely representative of the community;
however, only 23 subjects in the present analyses were
from this cohort. The majority (n=138) of incident AD
patients were identified in a later cohort from the
Washington Heights and Inwood Columbia Aging
Project, enrolled starting 1992. This cohort consists of
elders identified from a probability sample of Medicare
beneficiaries residing in the 14 census tracts comprising
the area of Manhattan between (approximately) 155th
and 181st streets. Access to the names of individuals was
provided by the Health Care Financing Administration.
The proportion of individuals within each ethnic group
and age stratum who participated in the study did not
differ significantly from the source population.
Participants were selected for the current study if
they were diagnosed with incident AD, that is, if they did
not meet criteria for dementia upon entry into the study,
but converted to a diagnosis of dementia at a follow-up
evaluation. Further, as we were interested in examining
disease course, we included only those subjects on whom
postincident data was available (eg, follow-up cognitive
assessment or mortality data). The final analysis included
161 subjects who were diagnosed with incident AD, had
follow-up data available, and continued to meet criteria
for dementia at their last evaluation. Two hundred
seventy two nondemented control cases were matched
with the incident AD sample on age, education, and
ethnicity, and included in the current study to provide
normative data for neuropsychologic measures.
Procedures
The study cohort was followed over a 15-year
period beginning in 1989 during which time each
participant received the same medical, neurologic, and
neuropsychologic evaluations at approximately 20-month
intervals. A physician elicited each subject’s medical and
neurologic history and conducted a standardized physical
and neurologic examination. All ancillary information
(medical charts, computed tomographies or magnetic
resonance imagings) was considered in the evaluation, if
available. Medical diagnoses were assigned when applic-
able. This examination was repeated at each follow-up.
Past medical history was recorded with specific attention
to stroke, trauma, medications, and recreational drug use.
Participants’ medical comorbidities were computed using
a modified version of the Charlson Index of Comorbi-
dity24 that assessed conditions including myocardial
infarct, congestive heart failure, peripheral vascular
disease, hypertension, chronic obstructive pulmonary
disease, arthritis, gastrointestinal disease, mild liver
disease, diabetes, chronic renal disease, and systemic
malignancy. All items received weights of 1, with the
exception of chronic renal disease and systemic malig-
nancy, which were weighted 2. For the current study,
subjects were assigned the maximum Charlson score
obtained during their participation in the study to
account for significant comorbidities arising at any point
before their death.
All participants underwent a standard neuropsy-
chologic battery that tested multiple domains including
memory, orientation, abstract reasoning, language, and
visuospatial abilities. The test battery included: The
Selective Reminding Test (SRT), a serial list learning
task comprised of recall and recognition components25;
the Benton Visual Retention Test (BVRT) forced-choice
recognition task in which participants are asked to
identify a geometric figure from an array of 4 figures
after an immediate delay26; orientation items from the
modified Mini-Mental State Examination8; Boston Nam-
ing Test27; Controlled Oral Word Association Test (CFL)
and Category Naming—Animals, Food, and Clothing28;
Boston Diagnostic Aphasia Examination (BDAE) Com-
plex Ideational Material and Repetition subtests29;
Wechsler Adult Intelligence Scales-Revised (WAIS-R)
Similarities subtest30; Mattis Dementia Rating Scale
(DRS)-Identities and Oddities subtest31; Rosen Drawing
Test32; and the BVRT perceptual matching task.26
Subjects were tested in English or Spanish according to
their preference.
Subjects performing below specified cutoff scores
for 2 memory measures, and in 2 other cognitive domains,
were considered to have sufficient cognitive impairment to
meet cognitive criteria for AD. These cutoff scores,
discussed in detail in an earlier paper,33 were selected
for their usefulness in distinguishing between normal
controls and patients with dementia. In addition to
impaired neuropsychologic performance, diagnosis of
AD required impairment in social or occupational
functioning as outlined by the Diagnostic and Statistical
Manual of Mental Disorders.34 Information from the
neurologic, psychiatric, and neuropsychologic assess-
ments was reviewed in a consensus conference comprised
of neurologists and neuropsychologists. On the basis
of this review, all participants were assigned to 1 of 3
categories: dementia, mild cognitive impairment, or
normal cognitive function. Only participants with in-
cident AD were included in this study. That is, they did
not meet criteria for dementia upon entry into the study,
and later converted to a diagnosis of dementia at a
follow-up evaluation. Subjects characterized as having
normal cognitive function were included as controls. All
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procedures were approved by the Institutional Review
Board at Columbia University Medical Center.
Statistical Analyses
Cox proportional hazard analysis was used to
determine the predictive use of demographic and neuro-
psychologic variables for mortality. Information regar-
ding mortality, the outcome of interest, was collected
through follow-up and the National Death Index.
Although age is sometimes used as the duration variable
in Cox models, the current study defined duration as time
from the AD diagnosis to death or last follow-up, the
specific time frame of interest. Given the clear association
between age and mortality, however, the predictive value
of age was evaluated in the first Cox proportional hazards
analysis, along with other potential predictors including
gender, education, global cognition, medical comorbi-
dities, and ethnicity. Gender was coded with male as the
reference category. Participants were categorized accord-
ing to ethnicity: Black (African-American, non-Hispanic),
White (non-Hispanic), or Hispanic; we used ethnicity as a
series of dummy variables with White as the reference
category. Years of education, global cognition (average
z-score of the 5 neuropsychologic indices), and medical
comorbidities were entered as continuous variables.
Variables that significantly predicted mortality in this
model were included as covariates in the remaining Cox
proportional hazards analyses.
Five additional Cox models examined the predictive
use of each neuropsychologic index measured at diag-
nosis, entered as a continuous variable predictor for
mortality. To create these indices, raw scores on
individual tests were converted into standardized z-scores
on the basis of the means and standard deviations of the
matched control group (Table 2). Individual test z-scores
were then averaged to create a single z-score for each
index. If fewer than half of the individual z-scores were
missing for a given domain, the composite score was
calculated using the existing data. If greater than half of
the tests were missing, the domain score was considered
missing data. The 5 neuropsychologic indices were
compiled to represent performance in areas including
Memory (SRT total recall; SRT delayed recall; BVRT
Recognition), Abstract Reasoning (WAIS Similarities;
Identities and Oddities), Visuospatial Functioning (Rosen
Drawing; BVRT Matching), Language (Boston Naming
Test; BDAE Repetition and Complex Ideational Material
subtests), and Verbal Fluency (Category Naming and
COWA). A follow-up repeated measures analysis of
variance was used to evaluate differences on neuropsy-
chologic indices, at diagnosis, across participants who
survived and those who died.
RESULTS
Thirty-nine subjects were lost to follow-up. This
group did not differ from the final sample (n=161) in
age, education, ethnicity, or scores on 4 of the 5
neuropsychologic indices. However, subjects lost to
follow-up had significantly lower medical comorbidities
(M=2.7, SD=1.8), t (192)=2.2, P=0.03, and higher
abstract reasoning scores at diagnosis (M=  0.6,
SD=0.7), t (208)=2.2, P=0.03 than subjects included
in the final analysis. The final group of 161 subjects with
incident AD was followed after incidence for an average
of 3.90 (2.69) years, with total follow-up times (from
diagnosis to last visit or death) ranging from 0.11 to 11.64
years. Fifty-two percent of the incident AD group
reached the mortality end point with a median survival
of 5.52 years (95% confidence interval, 4.41-6.63). Table 1
presents the demographic characteristics of the sample.
Table 2 presents the normative neuropsychologic data.
In the first Cox model, older age was associated
with higher risk of mortality (risk ratios, 1.08; 95%
confidence interval, 1.04-1.12), whereas Hispanic ethni-
city predicted lower mortality [0.22 (0.09-0.55)]. Gender
was nearly significant, whereas education, global cogni-
tion, and medical comorbidities were not significant
predictors (Table 3). Controlling for age, Hispanic
ethnicity, and gender in the remaining Cox models,
higher scores on the verbal fluency index at diagnosis
reduced the risk of mortality [0.71 (0.52-0.98); Table 3
and Fig. 1].
Significant variability in scores at the diagnostic
visit existed for all neuropsychologic indices with the
distribution of z-scores shown in Table 4.
A repeated measures analysis of variance with a
2 (survived, deceased) 5 (memory, language, abstract
reasoning, visuospatial functioning, and verbal fluency)
design was conducted to evaluate the relative differences
in verbal fluency and other neuropsychologic scores, at
diagnosis, in patients who died and in those who
remained alive. As this analysis excludes subjects who
have missing data for any of the neuropsychologic
indices, only 120 of 161 subjects were included. A
significant main effect was found for scores across the
5 neuropsychologic indices, F (4, 120)=16.97, P=0.000.
As expected, post-hoc t tests revealed that the entire
sample performed significantly lower on the memory
index than all other indices (P<0.01). Additionally,
verbal fluency was significantly lower than the language,
TABLE 1. Demographic and Clinical Characteristics of
Incident AD Group and Nondemented Controls
Incident AD
(n=161)
Nondemented
Controls (n=262)
Age M (SD) 82.73 (6.72) 80.12 (6.15)
Education M (SD) 7.10 (4.39) 8.24 (4.06)
Comorbidity Index M (SD) 3.56 (1.84) 2.69 (1.70)
Hispanic N (%) 89 (58%) 163 (60%)
African American N (%) 52 (34%) 77 (28%)
Caucasian N (%) 13 (8%) 32 (12%)
Memory  1.81 (0.45) NA
Abstract reasoning  0.90 (0.85) NA
Language  0.89 (0.92) NA
Visuospatial skills  0.92 (1.10) NA
Verbal fluency  1.16 (0.71) NA
Comorbidity Index indicates Modified Charlson Index of Comorbidity.
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abstract reasoning, and visuospatial processing indices
(P<0.01). Between group analyses demonstrated that
memory scores were equally low in both survivors and
nonsurvivors, but that the latter group seemed to drive
the decreased verbal fluency scores. There was no main
effect for group and no significant interaction effect;
however, differences across the survivors and nonsurvi-
vors approached significance on the verbal fluency index
only (P=0.06; Table 5 and Fig. 2).
DISCUSSION
Early AD is marked by a core amnestic syndrome
and heterogeneous deficits in visuospatial functioning,
language abilities, and executive skills.11,12,14–16,18,19,35
The various cognitive profiles seen in AD are thought to
reflect the relative distribution of neuropathology, and
have been associated with distinct functional neuroima-
ging patterns.11,18,19 For example, predominantly parietal
or prefrontal hypometabolism on positron emission
tomography, has been associated with disproportionately
impaired visuospatial and executive skills, respectively.11
Collectively, neuropsychologic and neuroimaging data
implicate multiple pathways by which AD neuropatho-
logy progresses, and reveal the regional disease expression
in individual patients. To the extent that different disease
pathways are associated with illness duration, early
neuropsychologic performance has the potential to in-
form survival estimates. The current study compared the
predictive value of numerous neuropsychologic measures
TABLE 2. Raw Neuropsychologic Scores in Nondemented Normative Sample Matched for
Age, Education, and Ethnicity
Test (Maximum Score Possible) Index N Mean SD
SRT total recall (72) Memory 266 38.95 8.57
SRT delayed recall (12) Memory 266 5.85 2.23
BVRT recognition (10) Memory 258 6.41 2.13
WAIS-R similarities (28) Abstract reasoning 260 8.97 6.38
DRS identities and oddities (16) Abstract reasoning 253 14.26 1.63
BNT (15) Language 254 13.58 1.59
BDAE repetition (8) Language 257 7.57 0.87
BDAE comprehension (6) Language 257 4.98 1.20
Rosen (5) Visuospatial 254 2.37 0.96
BVRT matching (10) Visuospatial 260 8.22 1.77
COWAT (N/A) Verbal fluency 256 8.53 3.47
Category Naming (N/A) Verbal fluency 259 13.40 3.41
BDAE indicates Boston Diagnostic Aphasia Examination; BNT, Boston naming Test; BVRT, Benton Visual
Recognition Test; COWA, Controlled Oral Word Association Test (CFL); DRS, Dementia Rating Scale; SRT, Selective
Reminding Test; WAIS-R, Wechsler Adult Intelligence Scales-Revised.
TABLE 3. Demographic and Neuropsychologic Predictors of
Mortality Incident AD
Predictors Risk Ratios 95% CI P
Age 1.08 1.04-1.12 0.00
Education 1.01 0.95-1.07 0.72
Gender 0.57 0.32-1.02 0.06
Global cognition 1.00 0.99-1.00 0.70
Comorbidity index 1.05 0.91-1.20 0.52
Hispanic 0.24 0.09-0.62 0.00
African American 0.56 0.22-1.45 0.23
Memory 0.95 0.58-1.54 0.82
Abstract reasoning 0.89 0.67-1.19 0.44
Visuospatial function 0.97 0.77-1.22 0.79
Language 1.07 0.82-1.40 0.63
Verbal fluency 0.71 0.52-0.98 0.04
Cox models for occurrence of death as predicted by demographic and
neuropsychologic variables in all subjects. Risk ratios and 95% confidence
intervals (CI) are tabulated, with significant findings in bold (95% CI not including
the value 1.0). Risk ratios for ethnicity are reported in reference to white subjects.
The 7 demographic variables were entered into 1 Cox model. Neuropsychologic
predictors were entered into 5 separate Cox models.
FIGURE 1. Probability of survival in incident AD as a function
of verbal fluency at diagnosis. Tertile values are reported in z-
scores. Small broken line indicates first tertile (VF < 1.50);
solid line, second tertile (1.50rVF< 0.91); large broken
line, third tertile (VFZ 0.91). VF indicates Verbal Fluency
Index.
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for mortality in a multiethnic, primarily community-
based study of incident AD.
The relevance of specific neuropsychologic deficits
for rate of AD progression has been explored only
minimally over the past 2 decades, and inconsistent
methodology has made it challenging to identify a
meaningful relationship between neuropsychologic per-
formance and mortality risk. Although an early study
suggested that severe aphasia was the best predictor of
mortality, the predictive use of other neuropsychologic
deficits was not evaluated.36 Further, subjects likely
varied in the etiology of their illness as the study’s
inclusion criteria did not require a memory deficit. A later
investigation found that in contrast to memory and
language scores, baseline visuoconstructional perfor-
mance best predicted mortality9; however, notably miss-
ing in this analysis was assessment of executive abilities.
The current study evaluated the predictive value of a
range of neuropsychologic abilities measured at diagnosis
in patients with incident AD. The index of verbal fluency
was the only significant neuropsychologic predictor of
mortality. At diagnosis, each additional unit of perfor-
mance on the fluency index (1 z-score, equivalent to
approximately 3.5 words on each test) was associated
with approximately a 30% risk reduction for reaching the
mortality end point. One possible interpretation of these
findings is that the prognostic value of verbal fluency
derives from its sensitivity to prefrontal, or frontal-
subcortical compromise. Both letter and category fluency
tasks have substantial executive demands, including
systematic search, word retrieval, and working memory
subserved in part by prefrontal circuitry.37 Theoretically,
category fluency draws more heavily than letter fluency
upon semantic networks supported by temporal cortex;
involvement of this area in early AD generally leads to
disproportionate impairment on category rather than
letter fluency.35,38,39 Accompanying deficits on letter
fluency, frequently observed further in the course of the
illness, are thought to reflect the extent to which
neuropathology impacts prefrontal cortex.40 As such,
more severe impairment on both fluency tasks at
diagnosis may signal a relatively rapid disease course, or
a qualitatively different disease presentation associated
with reduced survival.
At least 2 studies have linked rapid disease
progression in AD with early and disproportionate
executive dysfunction or prefrontal hypometabolism.19,21
Additionally, a recent study linked impaired performance
on verbal fluency and digit span backward to reduced
survival rates in patients with frontotemporal dementia.41
This finding may reflect the fact that patients with the
poorest prognosis, those with coexisting motor neuron
disease,41,42 may have the greatest difficulty on measures
of executive functioning; however, it is also possible that
independent of motor neuron disease, mortality risk may
increase with frontal-subcortical compromise to the
extent that corresponding symptoms of apathy eventually
contribute to akinetic-mutism, or that aspects of
behavioral disturbance lead to risky behaviors or
TABLE 4. Distribution of z-scores on Neuropsychologic Indices at Incident Visit
Memory Abstract Reasoning Language Visuospatial Skills Verbal Fluency
Minimum  3.2  3.2  3.3  3.3  3.6
25th percentile  2.1  1.3  1.5  1.8  1.6
50th percentile  1.8  0.8  0.8  0.8  1.2
75th percentile  1.5  0.2  0.2  0.2  0.7
Maximum  0.9 0.8 0.8 1.1 1.3
TABLE 5. Neuropsychologic Scores at Diagnosis by Mortality
in Incident AD Participants (Means and Standard Deviations)
Indices Surviving (n=58) Dead (n=62) P
Memory  1.79 (0.44)  1.75 (0.43) 0.81
Abstract reasoning  0.82 (0.85)  0.90 (0.87) 0.50
Visuospatial  0.98 (1.04)  0.89 (1.15) 0.68
Language  0.86 (0.96)  0.76 (0.85) 0.53
Verbal fluency  0.97 (0.72)  1.27 (0.72) 0.06
FIGURE 2. Neuropsychologic performance at diagnosis in
participants with incident AD. Solid line indicates deceased
group; broken line, living group; ME, Memory Index; AR,
Abstract Reasoning Index; VS, Visuospatial Index; LA, Lan-
guage Index; VF, Verbal Fluency Index.
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overmedication.41 Certainly the processes leading to
mortality differ across frontotemporal dementia and
AD; however, the latter hypothesis may be relevant for
the relationship between verbal fluency scores and
survival rates in the current study.
Alternatively, the prognostic value of verbal fluency
may be primarily a function of its psychometric properties
(eg, ample range, lack of floor, or ceiling effects). Verbal
fluency and other language scores have demonstrated
sensitivity to cognitive impairment across mild-to-mod-
erate AD in contrast to memory and visuospatial
measures which were optimally sensitive at the earlier
and later disease stages, respectively.10 To the extent that
verbal fluency measures are sensitive to cognitive change
across the duration of AD, such scores may offer greater
prognostic use than other neuropsychologic measures
that less closely track disease progression.
One limitation of the current study is that the
neuropsychologic battery was originally compiled for
diagnostic purposes, and is thus relatively limited in
scope. As a result, the selected neuropsychologic indices
may not comprehensively capture the stated constructs,
potentially preventing us from detecting a true relation-
ship between specific early deficits and mortality. It is also
true that certain measures have limited sensitivity owing
to ceiling effects in early AD. However, compilation of
the diagnostic measures into indices partially addresses
this issue, as is evidenced by the wide distribution of
scores on the visuospatial, language, and abstract reason-
ing indices at diagnosis. The variability in scores on each
index argues against the possibility that restricted range
limited the predictive value of certain indices for
mortality.
A second limitation of this study is that the
diagnostic algorithm may have constrained our findings
(ie, the memory index may not have been predictive of
mortality because subjects were required to demonstrate
impairment on 2 of 3 memory indices to meet criteria for
dementia). However, this is necessitated by the diagnostic
criteria for AD. Third, because the participants were not
autopsy-confirmed cases of AD, there is a risk that
participants with other forms of dementia were included
in this study. However, the applied standard diagnostic
criteria have a sensitivity of approximately 81% with a
specificity of approximately 70%.43 Further, all diagnoses
were subject to physician input at an experienced center,
and only those subjects who met criteria for AD at 2 visits
were included in the current analyses. Finally, our strict
cognitive inclusion criteria may have resulted in the
inclusion of slightly more impaired participants.
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